Whether the quantitative MRI technique will eventually replace x-ray technology in such studies is unclear, said Dr. Pelletier. “That's for regulatory bodies to decide,” he said.
“But it's quite clear that MRI is the technology of the future. It's very helpful, because you can truly speed up drug development in the field of OA and with less expense, using a smaller number of patients and in a shorter period of time.”
Dr. Jean-Pierre Pelletier and Dr. Johanne Martel-Pelletier are consultants for and shareholders in ArthroLab and ArthroVision. Jean-Pierre Raynauld is a consultant for ArthroVision. Dr. André Beaulieu, Dr. Louis Bassette, and Dr. Frédéric Morin received honoraria from ArthroLab. François Abram is an employee of ArthroVision. Marc Dorais is a consultant for ArthroVision. Dr. Altman had no relevant financial conflicts of interest.